Dr. Blayer oversees all vaccine process development and manufacturing activities for PATH and the nonclinical toxicology studies required to initiate first-in-human clinical trials. Based in Amsterdam, he is also a member of our Center for Vaccine Innovation and Access leadership team.
For more than two decades, Dr. Blayer has worked in vaccine development and production in biotech and multinational pharmaceutical companies throughout Europe and Asia. He brings diverse industry experience in all aspects of chemistry manufacturing control, including vaccine process development and optimization; production at scale; technology transfer; facility engineering; project management and leadership; and business development.
Prior to joining PATH in 2019, he founded the chemistry manufacturing control function at the Coalition for Epidemic Preparedness Innovations. As its first head, he led essential plans and activities for 26 separate vaccine projects. He was also the global project director for Batavia Biosciences in Leiden, the Netherlands. While there, he championed the RV3 rotavirus vaccine project in collaboration with Bio Farma and was an advisor to the Grand Challenges Inactivated Polio Vaccine Univercells project, among others.
Dr. Blayer is an Italian-Israeli national and earned his PhD in biochemical engineering from University College London.